MediWound - MDWD Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings or view top-rated stocks.

4 brokerages have issued 1-year price targets for MediWound's shares. Their MDWD share price forecasts range from $6.50 to $8.00. On average, they expect the company's stock price to reach $7.13 in the next twelve months. This suggests a possible upside of 293.6% from the stock's current price.
View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts.

MediWound's stock was trading at $2.36 at the beginning of 2022. Since then, MDWD shares have decreased by 23.3% and is now trading at $1.81.
View the best growth stocks for 2022 here.

MediWound saw a increase in short interest in July. As of July 15th, there was short interest totaling 176,700 shares, an increase of 259.9% from the June 30th total of 49,100 shares. Based on an average daily volume of 106,000 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the company's stock are short sold.
View MediWound's Short Interest.

MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our MDWD earnings forecast.

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings data on Tuesday, May, 17th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. The biopharmaceutical company earned $4.41 million during the quarter, compared to analysts' expectations of $4.35 million. MediWound had a negative net margin of 64.01% and a negative trailing twelve-month return on equity of 3,540.43%. During the same period in the previous year, the company earned ($0.10) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

MediWound's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sargent Investment Group LLC (1.58%) and Meitav Dash Investments Ltd. (0.85%).

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MDWD stock can currently be purchased for approximately $1.81.

MediWound (NASDAQ:MDWD) has a market capitalization of $59.98 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13,550,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

MediWound employs 77 workers across the globe.

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111.